Latest News and Press Releases

NEW HAVEN, Conn., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...

~ Highlights Continued Positive Sales Momentum and Estimated Year-End Cash Position ~ ~ Confirms Previously Announced Cost Savings Guidance ~ ~ Continues Senior Leadership Team Evolution with New...

NEW HAVEN, Conn., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...

~ Credit Facility has Option to be Converted into Preferred Shares ~ ~ Adjourns Special Meeting of Stockholders Scheduled for December 20, 2018 ~ ~ Reaffirms Product Sales and Cost Savings...

NEW HAVEN, Conn., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...

New Product Launches Continue to Make Progress Setting the Stage for Growth in 2019Entered Commercial Agreement with Menarini Group to market Vabomere®, Orbactiv® and Minocin® for Injection in 68...

NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...

– Met primary endpoint of Early Clinical Response at 96 hours after the first dose –  – Supplemental NDA expected to be filed with FDA in 1H 2019 – – Baxdela currently FDA approved for treatment of...

NEW HAVEN, Conn., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...

NEW HAVEN, Conn., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...